Skye Bioscience moving ahead with SBI-100 clinical trial after positive safety review
News release
by
Skye Bioscience Inc
New York
|
February 24, 2023 11:55 AM Eastern Standard Time
Skye Bioscience CEO Punit Dhillon joins Proactive's Natalie Stoberman to discuss the positive safety review for its Phase 2 clinical trial for its SBI-100 Ophthalmic Emulsion.
Dhillon said the trial's safety review committee has recommended that the trial continue without modification. Now, the company is preparing for Phase 3 recruitment for the third cohort of eight participants with dosing planned for March.
Contact Details
Proactive Investors US
+1 347-449-0879
